Changes in Plasma Levels of N-Arachidonoyl Ethanolamine and N-Palmitoylethanolamine following Bariatric Surgery in Morbidly Obese Females with Impaired Glucose Homeostasis

Akhila Mallipedhi, Sarah L. Prior, Gareth Dunseath, Richard M. Bracken, Jonathan Barry, Scott Caplin, Nia Eyre, James Morgan, John N. Baxter, Saoirse E. O’Sullivan, Sarir Sarmad, David A. Barrett, Stephen C. Bain, Steve D. Luzio, and Jeffrey W. Stephens

1Diabetes Research Group, Institute of Life Sciences, Swansea University, Swansea SA2 8PP, UK
2Department of Diabetes & Endocrinology, Morriston Hospital, ABM University Health Board, Swansea SA6 6NL, UK
3Welsh Institute of Metabolic and Obesity Surgery, Morriston Hospital, ABM University Health Board, Swansea SA6 6NL, UK
4Division of Medical Sciences and Graduate Entry Medicine, University of Nottingham, Royal Derby Hospital, Derby DE22 3DT, UK
5Centre for Analytical Bioscience, School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, UK

Correspondence should be addressed to Jeffrey W. Stephens; j.w.stephens@swansea.ac.uk

Received 1 December 2014; Revised 11 March 2015; Accepted 12 March 2015

Aim. We examined endocannabinoids (ECs) in relation to bariatric surgery and the association between plasma ECs and markers of insulin resistance. Methods. A study of 20 participants undergoing bariatric surgery. Fasting and 2-hour plasma glucose, lipids, insulin, and C-peptide were recorded preoperatively and 6 months postoperatively with plasma ECs (AEA, 2-AG) and endocannabinoid-related lipids (PEA, OEA). Results. Gender-specific analysis showed differences in AEA, OEA, and PEA preoperatively with reductions in AEA and PEA in females postoperatively. Preoperatively, AEA was correlated with 2-hour glucose ($r = 0.55$, $P = 0.01$), HOMA-IR ($r = 0.61$, $P = 0.009$), and HOMA %S ($r = −0.71$, $P = 0.002$). OEA was correlated with weight ($r = 0.49$, $P = 0.04$), fasting insulin ($r = 0.49$, $P = 0.04$), and HOMA-IR ($r = 0.48$, $P = 0.05$). PEA was correlated with fasting insulin ($r = 0.49$, $P = 0.04$). 2-AG had a negative correlation with fasting glucose ($r = −0.59$, $P = 0.04$). Conclusion. Gender differences exist in circulating ECs in obese subjects. Females show changes in AEA and PEA after bariatric surgery. Specific correlations exist between different ECs and markers of obesity and insulin and glucose homeostasis.

1. Introduction

Recently, considerable interest has developed in the role that the endocannabinoid system (ECS) plays in obesity, impaired glucose homeostasis, and type 2 diabetes mellitus (T2DM) [1]. The ECS comprises the endocannabinoids (ECs), the enzymes involved in their synthesis and degradation, and the cannabinoid (CB) receptors which are activated by ECs [2]. ECs are bioactive lipid mediators that are synthesised and released on demand [3]. The most comprehensively studied ECs are the fatty acid amides, N-arachidonoyl ethanolamine (AEA), N-palmitoylethanolamine (PEA), N-oleoylethanolamine (OEA), and related N-acylethanolamine (NAE) derivatives together with esters of arachidonic acid including 2-arachidonoylglycerol (2-AG) [4–7]. The ECS is critically important in the control and regulation of body weight both centrally and peripherally. For example, activation of CB1 by AEA and 2-AG is associated with increased food intake, weight gain, and obesity, whilst OEA and PEA are associated with the suppression of these effects. Debate
exists on whether PEA and OEA can be considered as endocannabinoid ligands as they have no activity at the classic cannabinoid receptors (CB1 and CB2) [8]. Increased levels of ECs have been observed in the circulation and visceral fat stores in obese subjects [9]; furthermore, adipocytes may synthesise ECs de novo [10]. Obese humans have elevated circulating levels of AEA and 2-AG compared to nonobese controls of both genders [11–13]. A previous study has shown higher circulating levels of 2-AG in insulin resistant obese postmenopausal women [14] and in obese younger females [15]. Overweight subjects with T2DM and hyperglycaemia also have higher circulating ECs compared to age- and body mass index- (BMI-) matched normoglycaemic subjects [10, 16].

Obesity is a major risk factor for insulin resistance and T2DM. Activation of the peripheral ECs has been observed in human obesity [11], resulting in adipogenesis, lipogenesis, hepatic steatosis, and increased insulin resistance [17, 18]. AEA is metabolised by fatty acid amide hydrolase (FAAH). Conflict exists within the literature with respect to FAAH activity in obesity. Studies have described reduced expression of FAAH in obese insulin resistant subjects [19]; other studies have observed a positive correlation between FAAH activity and BMI in a healthy population [20], but not in a bariatric sample of subjects [2]. The former observation of reduced FAAH in obese insulin resistant subjects together with the observation that increased adiposity or BMI may be associated with increased plasma ECs might result in a further incremental increase in ECs [12, 13, 21]. Sipe et al. demonstrated that circulating ECs predict obesity risk and suggested targeting ECs as a novel strategy for treating obesity [22]. Furthermore, CB1 receptor blockade ameliorates disturbances in glucose and insulin metabolism in mice fed a high-fat diet [23]. CB1 and CB2 receptor antagonists such as rimonabant have been studied within phase 3 clinical trials [24].

Bariatric surgery is an effective treatment for morbid obesity and is associated with reduced calorie intake, significant weight loss, and resolution of T2DM [25]. Little information is available on the effects of extreme weight loss, such as that associated with bariatric surgery in relation to the ECs. Of interest, a modest weight loss of 5% by diet or medication (sibutramine) did not influence circulating EC levels in postmenopausal women or obese subjects, respectively [11, 26], whereas a 10% weight reduction in abdominally obese men was associated with a reduction in 2-AG levels [27]. Downregulation of AEA and 2-AG following Roux-en-Y gastric bypass has been demonstrated in a rat model [28]. Furthermore, the effect of surgical gastric bypass-induced weight loss on changes in ECs on coronary circulatory dysfunction in morbidly obese individuals has been studied [29]. The aim of our current study was to examine gender differences in circulating ECs and changes in circulating ECs in relation to bariatric surgery (as an extreme weight loss intervention). ECs were measured preoperatively and 6 months postoperatively. We also studied the association between circulating ECs and markers of obesity and insulin and glucose homeostasis pre- and postoperatively.

2. Material and Methods

2.1. Study Participants. Approval for the study was obtained from the Local Research Ethics Committee (South West Wales; LREC reference 06/WMW02/7) and the Joint Scientific Research Committee at Swansea University and ABM University Health Board. Participants were identified and recruited from patients undergoing a planned bariatric surgical procedure at the Welsh Institute of Metabolic and Obesity Surgery (WIMOS) at Morriston Hospital, ABM University Health Board, Swansea, Wales, UK. Informed consent was obtained by trained personnel. Entry criteria at the outset of the study included both sexes, age > 18 years, BMI > 40 Kg/m², and being physically fit for surgery. All subjects had either previously diagnosed T2DM, impaired glucose regulation, or T2DM diagnosed during an oral 75 g glucose tolerance test (OGTT) at the start of the study. Participants with impaired glucose regulation were those with either impaired fasting glycaemia (IFG, 5.6–6.9 mmol/L) or impaired glucose tolerance (IGT, 2-hour glucose: 78–110.0 mmol/L) [30]. Participants with preexisting diabetes treated with diet, oral agents, GLP-1 analogues, or insulin were included. Participants with any acute concurrent illness were excluded. At the time of recruitment no participant volunteered a history of current or past cannabis use. We did not measure plasma cannabinoid levels.

2.2. Study Design. Participants were recruited prospectively from the bariatric surgical clinic and were not blindly allocated to a surgical treatment option. As per local guidance (within WIMOS) at the time, those with a BMI > 50 Kg/m² were routinely offered a biliopancreatic diversion (BPD), whereas those with a BMI below this were offered laparoscopic sleeve gastrectomy (LSG). LSG was performed as a standard procedure, that is, sleeve fashioned around a 32F bougie taken from 5 cm proximal to the pylorus and up to the left crus. BPD involved a distal gastrectomy (as described by Scopinaro et al. [31]) and a 50 cm common channel. All participants were recruited 1 month preoperatively and followed up postoperatively at 6 months. Patients underwent a standardised 75 g oral glucose tolerance test (OGTT) (122 mLs of Polycal 61.9 g/100 mL of glucose, Nutricia Clinical Care, Trowbridge, UK) pre- and postoperatively. There was no standardised meal prescribed for the night before and subjects were asked to fast from the midnight before the test with diabetes related medication omitted.

2.3. Baseline Clinical and Biochemical Information. At the time of the preoperative and postoperative OGTT the following clinical information was ascertained: age, gender, past medical history, treatment, and duration of diabetes. Baseline clinical measurements consisted of weight, height, BMI, waist circumference, and systolic and diastolic blood pressure. Baseline biochemical measurements (total cholesterol, low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), and triglycerides) were performed within the local hospital accredited laboratory. Fasting and 2-hour glucose, fasting lipids (Roche Modular P800 Analyser), and fasting insulin and C-peptide (Roche
2.4. Measurements of Insulin Sensitivity. The Homeosta-

sis Model Assessment (HOMA) was used to estimate steady state beta cell function (%B) and insulin sensi-
tivity (%S) preoperatively and postoperatively. These were calculated using the Oxford University online calculator (http://www.dtu.ox.ac.uk/homacalculator/, accessed May 7, 2013) [32]. HOMA-IR is the reciprocal of HOMA %S. HOMA %S represent values of 100% in normal young adults when using currently available assays for insulin, specific insulin, or C-peptide. The accuracy of these measures has been validated and has been shown to correlate with clamp-derived indices of insulin sensitivity and secretion [33]. The fasting C-peptide to insulin ratio was calculated as an index of hepatic insulin clearance [34].

2.5. Measurement of Plasma Endocannabinoid Levels. An LC-

esi-MS/MS method was used for analysis of ECs in human plasma samples based on a previously published method [35]. Fasting plasma samples were obtained preoperatively and postoperatively. Plasma was separated immediately and stored at –80°C immediately. Internal standards of 100 μL of 2-AG-d8 (10 μM) and 15 μL of AEA-d8 (28 μM) were added to aliquots of each plasma (0.4 mL) sample or blank sample (0.4 mL water) or EC standards and vortexed briefly. Ethyl acetate:hexane (9 : 1 v/v) was added to each sample, vortex-
mixed (10 min), and centrifuged (13000 rpm, 10 min, 4°C). The procedure was repeated and the supernatants pooled and evaporated using a vacuum centrifugal evaporator. Prior to analysis, each sample extract was reconstituted in 100 μL of acetonitrile. The injection volume was 10 μL. LC standards (AEA, 2-AG, OEA, PEA, and internal standards 2-AG-d8, AEA-d8) were purchased from Axxora Laboratory services, Bingham, Nottingham, UK. The HPLC system used was a Shimadzu SCL 10Avp (Shimadzu, Columbia, MD, USA) coupled to a triple quadrupole ion-trap 4000 QTRAP mass-spectrometer (ABI, UK) equipped with Turbo Spray ionisation interface. Analytes were separated chromatographically on a Waters Symmetry C18 column (internal diameter 100 × 2.1 mm, particle size 3.5 μm) with a mobile phase flow rate of 0.3 mL/minute. Multiple-reaction monitoring of individual compounds using specific precursor and product mass-to-charge (m/z) ratios allowed simultaneous measurement of AEA, 2-AG, OEA, and PEA.

2.6. Statistical Methods. Statistical analysis was performed using SPSS. Continuous variables that did not have a nor-

mal distribution (AEA, OEA, PEA, and 2-AG) underwent log transformation to normalise the data for analysis and are described with the geometric mean and approximate standard deviation. For continuous variables, differences in means were compared pre- and postoperatively using a paired sample t-test. Differences between males and females were compared by ANOVA. We also examined the correlation (Spearman’s correlation) between BMI, weight, waist circumferencen, fasting plasma glucose, 2-hour plasma glucose, glycated haemoglobin (HbA1c), systolic and diastolic blood pressure, fasting insulin, and markers of insulin resistance with plasma ECs pre- and postoperatively. In all cases a P < 0.05 was considered statistically significant.

As our aim was to examine the effects of bariatric surgery as an extreme weight loss intervention, we chose from the outset to examine the surgical groups together rather than separate. Our aim was therefore not to compare the effects of LSG and BPD. This would have also reduced the numbers to 10 within each group. As there are no previous studies performed in this group of subjects, a baseline power calculation was not performed. We also chose from the outset to examine for gender differences in circulating ECs.

3. Results

3.1. Participant Characteristics. Samples from twenty par-

icipants were analysed. Of these, 10 underwent LSG and 10 underwent BPD. There were 10 females and 10 males with a mean age of 49.8 ± 7 years. The baseline clinical characteristics pre- and postoperatively are shown in Table 1.

3.2. Weight, Blood Pressure, Lipids, and Glucose Control Pre-

and Postoperatively. As shown in Table 1 and in line with previous data, there was a significant mean weight reduction of 35.4 kg at 6 months. This was associated with significant reductions in waist circumference and BMI at 6 months. No statistically significant changes were observed in systolic and diastolic blood pressure, total cholesterol, LDL-C, and triglyceride levels postoperatively.

3.3. Effects of Bariatric Surgery on Glucose and Markers of

Insulin Resistance. As shown in Table 1, significant changes were observed in 2-hour plasma glucose and HbA1c at 6 months. Following surgery, 20% of the subjects had T2DM compared to 65% prior to surgery. There was a significant reduction in the fasting insulin and an increase in hepatic insulin clearance at 6 months postoperatively. HOMA %S was significantly increased at 6 months. There was no significant change in fasting C-peptide following surgery.

3.4. Effects of Bariatric Surgery on Circulating Plasma Endo-
cannabinoid Levels. In the sample as a whole, there were no significant changes in circulating levels of AEA, OEA, PEA, and 2-AG postoperatively (Table 1). We observed significant differences in circulating levels of AEA, OEA, and PEA between males and females preoperatively (Table 2). Furthermore, in the females, significant reductions were observed in postoperative circulating AEA and PEA compared to preoperative circulating AEA and PEA (Table 2). Of interest, the postoperative levels in the females were comparable to the levels in the males pre- and postoperatively. No gender differences in circulating ECs were observed postoperatively.

3.5. Temporal Correlations between BMI, Glycaemic Con-
trol, Insulin Resistance, and Endocannabinoids. As described
within the methods, we chose from the outset to examine the correlation between markers of obesity and insulin and glucose homeostasis and ECs preoperatively and postoperatively. The results are shown in Table 3. For AEA, preoperatively, there were significant positive correlations with 2-hour plasma glucose ($r = 0.55, P = 0.01$), HOMA-IR ($r = 0.61, P = 0.009$), and a negative correlation with HOMA %S ($r = -0.71, P = 0.002$); these were no longer present postoperatively. Preoperatively, OEA had a significant correlation with weight ($r = 0.49, P = 0.03$), waist circumference ($r = 0.52, P = 0.02$), fasting insulin ($r = 0.49, P = 0.04$), and HOMA-IR ($r = 0.48, P = 0.05$). With respect to PEA, preoperatively, there was a positive correlation with fasting insulin ($r = 0.49, P = 0.04$) and LDL-C ($r = 0.44, P = 0.04$) and 2-AG had a negative correlation with fasting plasma glucose ($r = -0.59, P = 0.04$).

4. Discussion

In line with previous studies, we observed significant improvements in T2DM following bariatric surgery [36–38]. Using the American Diabetes Association criteria for the diagnosis of diabetes based on plasma glucose, we observed that 80% of participants had normal glucose levels during the postoperative OGTT. Within the current study group, we observed significant improvements postoperatively in glycaemic control, insulin sensitivity (HOMA %S), and hepatic insulin clearance.
Table 3: Correlations between circulating ECs and markers of obesity and insulin and glucose homeostasis pre- and postoperatively.

| Variable           | AEA       | OEA       | PEA       | 2-AG      |
|--------------------|-----------|-----------|-----------|-----------|
| **BMI**            |           |           |           |           |
| 0 months           | 0.17 (0.68) | 0.42 (0.06) | 0.30 (0.19) | 0.07 (0.45) |
| 6 months           | 0.24 (0.32) | 0.17 (0.50) | −0.21 (0.93) | −0.16 (0.53) |
| **Weight**         |           |           |           |           |
| 0 months           | 0.10 (0.68) | 0.49 (0.03) | 0.36 (0.12) | 0.20 (0.45) |
| 6 months           | 0.01 (0.96) | 0.01 (0.97) | −0.23 (0.35) | −0.16 (0.53) |
| **Waist**          |           |           |           |           |
| 0 months           | 0.10 (0.68) | 0.52 (0.02) | 0.40 (0.08) | 0.26 (0.33) |
| 6 months           | −0.13 (0.62) | −0.04 (0.86) | −0.28 (0.25) | 0.11 (0.70) |
| **Fasting glucose**|           |           |           | −0.59 (0.04)|
| 0 months           | 0.15 (0.55) | 0.05 (0.84) | 0.09 (0.71) | −0.59 (0.04) |
| 6 months           | 0.54 (0.05) | 0.11 (0.62) | 0.18 (0.46) | −0.09 (0.75) |
| **2-hour glucose** |           |           |           |           |
| 0 months           | 0.55 (0.01) | 0.11 (0.65) | 0.17 (0.47) | 0.003 (1.00) |
| 6 months           | −0.02 (0.94) | −0.24 (0.33) | −0.13 (0.60) | −0.42 (0.10) |
| **HbA1c**          |           |           |           |           |
| 0 months           | 0.44 (0.06) | 0.22 (0.37) | 0.20 (0.40) | −0.12 (0.66) |
| 6 months           | 0.09 (0.71) | −0.13 (0.59) | −0.00 (0.97) | −0.35 (0.17) |
| **Fasting insulin**|           |           |           |           |
| 1 month            | 0.28 (0.26) | 0.49 (0.04) | 0.49 (0.04) | 0.18 (0.54) |
| 6 months           | −0.03 (0.89) | 0.06 (0.81) | 0.08 (0.76) | −0.19 (0.49) |
| **HOMA S%**        |           |           |           |           |
| 1 month            | −0.71 (0.002) | −0.34 (0.18) | −0.47 (0.06) | 0.16 (0.57) |
| 6 months           | −0.35 (0.16) | −0.25 (0.33) | −0.33 (0.18) | −0.21 (0.44) |
| **HOMA-IR**        |           |           |           |           |
| 0 months           | 0.61 (0.009) | 0.48 (0.05) | 0.53 (0.03) | 0.27 (0.32) |
| 6 months           | 0.40 (0.1) | 0.28 (0.27) | 0.25 (0.31) | 0.38 (0.15) |
| **Systolic BP**    |           |           |           |           |
| 0 months           | 0.40 (0.09) | 0.11 (0.66) | 0.25 (0.30) | −0.01 (1.0) |
| 6 month            | −0.13 (0.61) | −0.27 (0.26) | −0.06 (0.81) | −0.07 (0.78) |
| **Diastolic BP**   |           |           |           |           |
| 0 months           | 0.48 (0.04) | 0.01 (0.96) | 0.14 (0.56) | −0.52 (0.04) |
| 6 months           | −0.06 (0.83) | −0.08 (0.76) | 0.08 (0.74) | −0.23 (0.38) |
| **LDL-C**          |           |           |           |           |
| 0 months           | 0.15 (0.54) | 0.15 (0.52) | 0.44 (0.04) | −0.02 (0.94) |
| 6 months           | −0.27 (0.27) | −0.26 (0.28) | −0.04 (0.87) | 0.13 (0.62) |
| **HDL-C**          |           |           |           |           |
| 0 months           | −0.21 (0.37) | −0.12 (0.53) | −0.31 (0.18) | −0.73 (0.001) |
| 6 months           | −0.32 (0.18) | 0.18 (0.45) | 0.28 (0.25) | 0.03 (0.91) |
| **2-AG**           |           |           |           |           |
| 0 months           | 0.08 (0.76) | −0.01 (0.98) |           |           |
| 6 months           | 0.52 (0.02) | 0.60 (0.005) |           |           |

The r values are shown with the P values in brackets. Significant correlations are shown in bold.
Our aim was to examine changes in circulating ECs in relation to bariatric surgery (as a weight loss intervention), differences by gender, and the association between plasma ECs and markers of insulin resistance before and after bariatric surgery. In the whole group, prior to gender stratification, we observed no changes in circulating AEA, OEA, PEA, and 2-AG before and after bariatric surgery. This is in line with previous studies where a modest weight loss of 5% by diet or medication (sibutramine) did not influence circulating ECs in postmenopausal women or obese subjects, respectively [11, 26], but contradicts the effect of 10% weight loss on 2-AG and AEA levels reported for obese men [27] and an increase in PEA in postmenopausal women [14] with a mean BMI of 32.9 Kg/m². This may be due to the extremely high BMI both pre- and postoperatively despite surgical induced weight loss and may be unique to our study sample. We observed significant gender differences preoperatively which is in line with a previous study which described gender differences in circulating levels of AEA, OEA, and PEA [14]. Postoperatively, we observed significant reductions in circulating AEA and PEA in females but not males. Of note, there was no significant difference in weight, BMI, and waist circumference between females and males preoperatively or postoperatively. Furthermore, no significant differences were observed between gender (females versus males) for changes postoperatively in weight (38±18 versus 33±24 kg, P = 0.58), BMI (14.0 ± 7.5 versus 9.6 ± 7.0 kg/m², P = 0.20), and waist circumference (21.3 ± 6.8 versus 19.2 ± 6.8 cm, P = 0.52).

No gender differences were seen for postoperative changes in fasting glucose, 2-hour glucose, fasting insulin, HbA1c, and HOMA measurements. Therefore, the reason for this gender difference is unclear but is likely to be related to an interaction between sex hormones and the ECS. This is supported by previous literature [39, 40] which supports a role for female sex hormones in modulating EC activity. We would therefore suggest that, for further studies examining circulating ECs, gender stratification is essential. A limitation of our current study was that we did not measure sex hormones nor did we document menstrual history, but none of the female participants had reported menopausal symptoms.

There is paucity in the published literature examining the associations between circulating ECs and markers of fat mass and glucose and insulin homeostasis. We observed distinct associations between specific ECs and these markers. Previous studies have shown that weight and waist circumference are accepted markers of insulin resistance [41] and that circulating EC levels are associated with insulin resistance [10, 16, 42]. Preoperatively, AEA had significant correlations with 2-hour plasma glucose and markers of insulin resistance. OEA was correlated with weight, waist circumference, and insulin resistance. PEA had a positive correlation insulin and 2-AG with fasting glucose. Therefore, the different ECs appear to be associated with different markers of fat mass and glucose and insulin homeostasis. However, AEA was correlated with OEA and PEA. Therefore, there appear to be complex and specific biochemical-clinical relationships. These findings have not been described previously and warrant further investigation. None of the above correlations were observed postoperatively. One possible explanation for this may be related to a change in diet following bariatric surgery. A recent study has shown that obesity and high fat dietary intake influences CB₁ receptor expression in skeletal muscle and FAAH gene expression in subcutaneous adipose tissue [43]. These effects were not observed in lean and low fat diets. Another explanation is that genetic variation within CB₁ receptor may influence metabolic function in response to changes in diet or medication [44, 45]. Another possible explanation may be related to changes in other satiety hormones which influence the ECS. These may include ghrelin and leptin, both of which are influenced by bariatric surgery [46, 47] and other means of weight reduction [48]. This is an area which warrants further investigation.

Therapeutic interventions which target the ECS through the blockade of CB₁ receptors have been extensively studied and have shown benefits in glucose metabolism and insulin resistance [21, 23, 49]. To the best of our knowledge, this current study is the only one that has examined the relationship of ECs following extreme weight loss resulting from bariatric surgery. Further work is required to explore these findings to establish whether circulating ECs may have a causal association with obesity and impaired glucose and insulin homeostasis or whether they are merely a marker of increased fat mass and associated metabolic dysregulation. The gender differences relating to the ECs also require more detailed examination. The current study adds to the available literature examining the role of ECs in obesity and glucose and insulin homeostasis. A limitation of our current study is that this comprised a small number of 20 subjects. In view of this number, we combined the two types of surgeries which we acknowledge involve dissimilar mechanisms to induce weight loss. The study was explorative in nature and the data will add to the potential for a more robust larger powered study within this interesting field of investigation. Furthermore, future studies should examine the different bariatric procedures in relation to circulating ECs.

Ethical Approval

Approval for the study was obtained from the Local Research Ethics Committee (South West Wales; LREC reference 06/WMW02/7) and the Joint Scientific Research Committee at Swansea University and ABM University Health Board.

Consent

All participants gave their informed consent prior to their inclusion in the study.

Conflict of Interests

The authors declare that there is no conflict of interests associated with this paper. None of the authors are in a financial relationship with the organization that sponsored the research.
Acknowledgments

This study was supported by a Project Research Grant from the BUPA Foundation (33NOV06). The authors thank Dr. Rachel Still and the staff of the Department of Clinical Chemistry at Morriston Hospital, ABM University Health Board, for their assistance and collaboration in measuring glucose, insulin, and C-peptide.

References

[1] B. Horvth, P. Mukhopadhyay, G. Hask, and P. Pacher, “The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications,” The American Journal of Pathology, vol. 180, no. 2, pp. 432–442, 2012.
[2] J. C. Cable, G. D. Tan, S. P. Alexander, and S. E. O’Sullivan, “The effects of obesity, diabetes and metabolic syndrome on the hydrolytic enzymes of the endocannabinoid system in animal and human adipocytes,” Lipids in Health and Disease, vol. 13, no. 1, article 43, 2014.
[3] P. Pacher, S. Bátkai, and G. Kunos, “The endocannabinoid system as an emerging target of pharmacotherapy,” Pharmacological Reviews, vol. 58, no. 3, pp. 389–462, 2006.
[4] V. di Marzo, A. Fontana, H. Cadas et al., “Formation and inactivation of endogenous cannabinoid anandamide in central neurons,” Nature, vol. 372, no. 6507, pp. 686–691, 1994.
[5] V. Di Marzo and D. G. Deutsch, “Biochemistry of the endogenous ligands of cannabinoid receptors,” Neurobiology of Disease, vol. 5, no. 6, pp. 386–404, 1998.
[6] V. Di Marzo, T. Bisogno, L. de Petrocellis, D. Melck, and B. R. Martin, “Cannabinimimetic fatty acid derivatives: the anandamide family and other endocannabinoids,” Current Medicinal Chemistry, vol. 6, no. 8, pp. 721–744, 1999.
[7] J. M. Walker, J. E. Krey, C. J. Chu, and S. M. Huang, “Endocannabinoids and related fatty acid derivatives in pain modulation,” Chemistry and Physics of Lipids, vol. 121, no. 1-2, pp. 159–172, 2002.
[8] M. F. Bennetzen, “Investigations of the endocannabinoid system in adipose tissue: effects of obesity/weight loss and treatment options,” Danish Medical Bulletin, vol. 58, no. 4, Article ID B4269, 2011.
[9] M.-P. Gonthier, L. Hoareau, F. Festy et al., “Identification of endocannabinoids and related compounds in human fat cells,” Obesity, vol. 15, no. 4, pp. 837–845, 2007.
[10] I. Matias, M.-P. Gonthier, P. Orlando et al., “Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 8, pp. 3171–3180, 2006.
[11] S. Engeli, J. Böhnke, M. Feldpausch et al., “Activation of the peripheral endocannabinoid system in human obesity,” Diabetes, vol. 54, no. 10, pp. 2838–2843, 2005.
[12] M. Côté, I. Matias, I. Lemieux et al., “Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men,” International Journal of Obesity, vol. 31, no. 4, pp. 692–699, 2007.
[13] M. Blüher, S. Engeli, N. Klötting et al., “Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity,” Diabetes, vol. 55, no. 11, pp. 3053–3060, 2006.
[14] J. Abdulnour, S. Yasari, R. Rabasa-Lhoret et al., “Circulating endocannabinoids in insulin sensitive vs. Insulin resistant obese postmenopausal women. A MONET group study,” Obesity (Silver Spring), vol. 22, no. 1, pp. 211–216, 2014.
[15] F. Fernández-Aranda, S. Sauchelli, A. Pastor et al., “Moderate-vigorous physical activity across body mass index in females: moderating effect of endocannabinoids and temperament,” PLoS ONE, vol. 9, no. 8, Article ID e104534, 2014.
[16] V. Di Marzo, A. Verrijken, A. Hakkarainen et al., “Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects,” European Journal of Endocrinology, vol. 161, no. 5, pp. 715–722, 2009.
[17] V. Di Marzo, “The endocannabinoid system in obesity and type 2 diabetes,” Diabetologia, vol. 51, no. 8, pp. 1356–1367, 2008.
[18] G. Kunos and J. Tam, “The case for peripheral CB1 receptor blockade in the treatment of visceral obesity and its cardiometabolic complications,” British Journal of Pharmacology, vol. 163, no. 7, pp. 1423–1431, 2011.
[19] T. M. D’Onofrio, K. A. Pierce, J. J. Roix, A. Tyler, H. Chen, and S. R. Teixeira, “The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids,” Diabetes, vol. 57, no. 5, pp. 1262–1268, 2008.
[20] J. C. Cable, G. D. Tan, S. P. Alexander, and S. E. O’Sullivan, “The activity of the endocannabinoid metabolising enzyme fatty acid amide hydrolase in subcutaneous adipocytes correlates with BMI in metabolically healthy humans,” Lipids in Health and Disease, vol. 10, article 129, 2011.
[21] D. Kota, G. Marsicano, M. Tschöp et al., “The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis,” Journal of Clinical Investigation, vol. 112, no. 3, pp. 423–431, 2003.
[22] J. C. Sipe, T. M. Scott, S. Murray et al., “Biomarkers of endocannabinoid system activation in severe obesity,” PLoS ONE, vol. 5, no. 1, Article ID e8792, 2010.
[23] C. R. Trillou, M. Arnone, C. Delgorge et al., “Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice,” The American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 284, no. 2, pp. R345–R353, 2003.
[24] V. K. Vemuri, D. R. Janero, and A. Makriyannis, “Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome,” Physiology and Behavior, vol. 93, no. 4-5, pp. 671–686, 2008.
[25] H. Buchwald, Y. Avidor, E. Braunwald et al., “Bariatric surgery: a systematic review and meta-analysis,” Journal of the American Medical Association, vol. 292, no. 14, pp. 1724–1737, 2004.
[26] S. Engeli, K. Heusser, J. Janke et al., “Peripheral endocannabinoid system activity in patients treated with sibutramine,” Obesity, vol. 16, no. 5, pp. 1135–1137, 2008.
[27] V. Di Marzo, M. Côté, I. Matias et al., “Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: Associations with changes in metabolic risk factors,” Diabetologia, vol. 52, no. 2, pp. 213–217, 2009.
[28] A. Guigarro, D. Osei-Hyiaman, J. Harvey-White et al., “Sustained weight loss after Roux-en-Y gastric bypass is characterized by down regulation of endocannabinoids and mitochondrial function,” Annals of Surgery, vol. 247, no. 5, pp. 779–790, 2008.
[29] A. Quercioli, F. Montecucco, Z. Pataky et al., “Improvement in coronary circulatory function in morbidly obese individuals
after gastric bypass-induced weight loss: relation to alterations in endocannabinoids and adipocytokines,” *European Heart Journal*, vol. 34, no. 27, pp. 2063–2073, 2013.

[30] G. Domínguez-Vega, M. Pera, J. M. Ramón et al., “A comparison of laparoscopic versus open repair for the surgical treatment of perforated peptic ulcers,” *Cirugía Espanola*, vol. 91, no. 6, pp. 372–377, 2013.

[31] N. Scopinaro, E. Gianetta, D. Civalleri, U. Bonalumi, and V. Bachi, “Bilio-pancreatic bypass for obesity: I. An experimental study in dogs,” *British Journal of Surgery*, vol. 66, no. 9, pp. 613–617, 1979.

[32] J. C. Levy, D. R. Matthews, and M. P. Hermans, “Correct homeostasis model assessment (HOMA) evaluation uses the computer program,” *Diabetes Care*, vol. 21, no. 12, pp. 2191–2192, 1998.

[33] G. I. Uwaifo, E. M. Fallon, J. Chin, J. Elberg, S. I. Parikh, and J. A. Yanovski, “Indices of insulin action, disposal, and secretion derived from fasting samples and clamp for normal glucose-tolerant black and white children,” *Diabetes Care*, vol. 25, no. 11, pp. 2081–2087, 2002.

[34] K. N. Bojsen-Møller, C. Dirksen, N. B. Jørgensen et al., “Increased hepatic insulin clearance after Roux-en-Y gastric bypass,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 98, no. 6, pp. E1066–E1071, 2013.

[35] D. Richardson, C. A. Ortori, V. Chapman, D. A. Kendall, and D. A. Barrett, “Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry,” *Analytical Biochemistry*, vol. 360, no. 2, pp. 216–226, 2007.

[36] D. Benailles, J. A. Flores-Le-Roux, J. Pedro-Botet et al., “Sleeve gastrectomy and Roux-en-Y gastric bypass are equally effective in correcting insulin resistance,” *International Journal of Surgery*, vol. 11, no. 4, pp. 309–313, 2013.

[37] F. Leonetti, D. Capoccia, F. Coccia et al., “Obesity, type 2 diabetes mellitus, and other comorbidities: a prospective cohort study of laparoscopic sleeve gastrectomy vs medical treatment,” *Archives of Surgery*, vol. 147, no. 8, pp. 694–700, 2012.

[38] A. Jiménez, R. Casamitjana, L. Flores et al., “Long-term effects of sleeve gastrectomy and roux-en-y gastric bypass surgery on type 2 diabetes mellitus in morbidly obese subjects,” *Annals of Surgery*, vol. 256, no. 6, pp. 1023–1029, 2012.

[39] R. M. Craft, J. A. Marusich, and J. L. Wiley, “Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system?” *Life Sciences*, vol. 92, no. 8–9, pp. 476–481, 2013.

[40] T. Karasu, T. H. Marczylo, M. Maccarrone, and J. C. Konje, “The role of sex steroid hormones, cytokines and the endocannabinoid system in female fertility,” *Human Reproduction Update*, vol. 17, no. 3, Article ID dmuq058, pp. 347–361, 2011.

[41] D. G. Carey, A. B. Jenkins, L. V. Campbell, J. Freund, and D. J. Chisholm, “Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM,” *Diabetes*, vol. 45, no. 5, pp. 633–638, 1996.

[42] I. Matias, M.-P. Gonthier, S. Petrosino et al., “Role and regulation of acylethanolamides in energy balance: focus on adipocytes and β-cells,” *British Journal of Pharmacology*, vol. 152, no. 5, pp. 676–690, 2007.

[43] S. Engeli, A.-C. Lehmann, J. Kaminiski et al., “Influence of dietary fat intake on the endocannabinoid system in lean and obese subjects,” *Obesity*, vol. 22, no. 5, pp. E70–E76, 2014.

[44] D. A. de Luis, H. F. Ovalle, G. D. Soto, O. Izaola, B. de la Fuente, and E. Romero, “Role of genetic variation in the cannabinoid receptor gene (CNR1) (G1359A Polymorphism) on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2,” *Journal of Investigative Medicine*, vol. 62, no. 2, pp. 324–327, 2014.

[45] D. A. de Luis, R. Aller, M. G. Sagrado, R. Conde, O. Izaola, and B. de la Fuente, “Genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism) and their influence on anthropometric parameters and metabolic parameters under a high monounsaturated vs. high polyunsaturated fat hypocaloric diets,” *Journal of Nutritional Biochemistry*, vol. 24, no. 8, pp. 1431–1435, 2013.

[46] M. Tsoli, A. Chroniaou, I. Kehagias, F. Kalfarentzos, and T. K. Alexandrides, “Hormone changes and diabetes resolution after biliopancreatic diversion and laparoscopic sleeve gastrectomy: a comparative prospective study,” *Surgery for Obesity and Related Diseases*, vol. 9, no. 5, pp. 667–677, 2013.

[47] D. Bradley, C. Conte, B. Mittendorfer et al., “Gastric bypass and banding equally improve insulin sensitivity and beta cell function,” *The Journal of Clinical Investigation*, vol. 122, no. 12, pp. 4667–4674, 2012.

[48] C. Mason, L. Xiao, I. Imayama et al., “The effects of separate and combined dietary weight loss and exercise on fasting ghrelin concentrations in overweight and obese women: a randomized controlled trial,” *Clinical Endocrinology*, vol. 82, no. 3, pp. 369–376, 2015.

[49] D. Osei-Hyiaman, J. Liu, L. Zhou et al., “Hepatic CBl receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice,” *The Journal of Clinical Investigation*, vol. 118, no. 9, pp. 3160–3169, 2008.